Impact of systemic antimicrobial therapy on the faecal microbiome in symptomatic dairy cows

PLoS One. 2024 Jan 5;19(1):e0296290. doi: 10.1371/journal.pone.0296290. eCollection 2024.

Abstract

Antimicrobial resistance is a global threat to human and animal health, with the misuse and overuse of antimicrobials suggested as the main drivers of resistance. Antimicrobial therapy can alter the bacterial community composition and the faecal resistome in cattle. Little is known about the impact of systemic antimicrobial therapy on the faecal microbiome in dairy cows in the presence of disease. Therefore, this study aimed to assess the impact of systemic antimicrobial therapy on the faecal microbiome in dairy cows in the pastoral farm environment, by analysing faecal samples from cattle impacted by several different clinically-defined conditions and corresponding antimicrobial treatments. Analysis at the individual animal level showed a decrease in bacterial diversity and richness during antimicrobial treatment but, in many cases, the microbiome diversity recovered post-treatment when the cow re-entered the milking herd. Perturbations in the microbiome composition and the ability of the microbiome to recover were specific at the individual animal level, highlighting that the animal is the main driver of variation. Other factors such as disease severity, the type and duration of antimicrobial treatment and changes in environmental factors may also impact the bovine faecal microbiome. AmpC-producing Escherichia coli were isolated from faeces collected during and post-treatment with ceftiofur from one cow while no third-generation cephalosporin resistant E. coli were isolated from the untreated cow samples. This isolation of genetically similar plasmid-mediated AmpC-producing E. coli has implications for the development and dissemination of antibiotic resistant bacteria and supports the reduction in the use of critically important antimicrobials.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • Cattle
  • Escherichia coli
  • Feces
  • Female
  • Humans
  • Microbiota*

Substances

  • Anti-Infective Agents
  • Anti-Bacterial Agents

Grants and funding

This work was funded by the AgResearch Strategic Science Investment Fund Food Integrity programme (AC, GB), the New Zealand Food Safety Science and Research Centre (AC, RC) and the School of Veterinary Science, Massey University Postgraduate Research Fund (RC). Rose Collis was the recipient of a New Zealand Food Safety Science and Research Centre PhD scholarship (RC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.